Why the Pro Medicus (ASX:PME) share price is getting thumped today

The Pro Medicus Limited (ASX:PME) share price is sinking on Wednesday after its half year result fell short of expectations…

| More on:
asx share price fall represented by investor with head in hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has come under pressure this morning following the release of its half year results.

In early trade, the health imaging company's shares were down as much as 17% to $38.00.

The Pro Medicus share price has since recovered slightly but remains 8% lower at $41.83 at the time of writing.

Why is the Pro Medicus share price crashing lower?

Investors have been selling Pro Medicus shares on Wednesday after its half year results fell short of the market's lofty expectations.

For the six months ended 31 December, the company reported a 7.8% increase in revenue to $31.6 million. Management advised that the stronger Australian dollar impacted its result. On a constant currency basis, its revenue would have been up 12.4% to $32.9 million.

Currency headwinds also weighed on its profits. Reported underlying profit before tax came in 25.9% higher at $18.76 million but would have been up 29% to $19.7 million in constant currency.

On the bottom line, Pro Medicus delivered a 12.4% increase in net profit after tax to $13.5 million. This includes tax expense of $4.66 million, which represents a tax rate of 25.6%. This compares to a tax rate of 18.6% in 2019.

At the end of the period, the company had cash reserves of $50.9 million and no debt.

This strong balance sheet allowed the Pro Medicus board to declare a fully franked interim dividend of 7 cents per share.

How does this compare to expectations?

According to a note out of Goldman Sachs, Pro Medicus missed on both revenue and earnings.

The broker notes that Pro Medicus feel short of its revenue forecast by 9% and its EBIT forecast by 7%.

This goes some way to explaining the weakness in the Pro Medicus share price today.

What were the drivers of its growth?

Pro Medicus' CEO, Dr Sam Hupert, revealed that the company performed well across all markets despite the restrictions of COVID-19.

He said: "It was a good six months across all jurisdictions. Examination numbers in the first three months of the quarter were still recovering from their April 2020 lows however we were able to make up for the decrease with new clients coming on stream and exam numbers tracking back to pre COVID levels."

The star of the show for the company was arguably the Australian business, which delivered a 22.8% increase in revenue. This was largely due to the rollout of the Healius Ltd (ASX: HLS) contract and the extension of a contract with I-MED.

The company's European operations also had a positive half. This is expected to continue in the second half thanks to its new contract with Ludwig-Maximilians University.

Outlook

No guidance or commentary was given in regard to its second half outlook. This may have disappointed investors and be contributing to the Pro Medicus share price decline today. Though, it is worth noting that this is customary for Pro Medicus.

Positively, Dr Hupert did speak briefly about the company's sales pipeline.

He said: "We have had a very good run of contract wins over the past seven to eight months and pleasingly we have seen an increasing number of opportunities enter the pipeline in addition to those opportunities that have been progressing through the sales cycle. Importantly, the opportunities are across a range of market segments, including some for multiple Visage products, as well as a healthy mix of Cloud and non-Cloud."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »